Greg Brown, CEO of ImpediMed, said: “Metagenics has been an outstanding Australian partner using ImpediMed’s body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles.”
Mike Katke, vice president of medical marketing at Metagenics, said: “We’ve seen the synergies of combining ImpediMed’s products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals. Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision.”